Trimethoprim sulfamethoxazole (TMP-SMX)
Specialities: Diagnostic radiology · Infectious diseases · Intensive care medicine · Internal medicine · Orthopedic surgery · Pathology · Pulmonary medicine
Specialities: Diagnostic radiology · Infectious diseases · Intensive care medicine · Internal medicine · Orthopedic surgery · Pathology · Pulmonary medicine
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
Pneumonitis (interstitial lung disease/ILD)
Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
Acute eosinophilic pneumonia (AEP)
Acute fibrinous organizing pneumonia (AFOP)
Irreversible respiratory damage requiring lung Tx
DRES syndrome - DRESS-like reaction
Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
Anaphylaxis-Anaphylactoid reaction (can be fatal)
Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
ANCA positivity. Subclinical or with clinical manifestations
Path: NSIP-cellular pattern (see also Ia, Ib)
Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
Path: NSIP-fibrotic pattern
Path: Resolving alveolar damage
Path: Delayed Alveolar Injury with Delayed Epithelialization (DAIDE)